GoodRx Holdings
GDRX
216 hedge funds and large institutions have $4.99B invested in GoodRx Holdings in 2021 Q4 according to their latest regulatory filings, with 54 funds opening new positions, 63 increasing their positions, 61 reducing their positions, and 54 closing their positions.
4.25% more ownership
Funds ownership: 185.06% → 189.31% (+4.3%)
3% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 61
0% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 54
1% less funds holding
Funds holding: 218 → 216 (-2)
13% less capital invested
Capital invested by funds: $5.73B → $4.99B (-$737M)
16% less call options, than puts
Call options by funds: $58.4M | Put options by funds: $69.5M
38% less funds holding in top 10
Funds holding in top 10: 8 → 5 (-3)
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$329M |
| 2 |
ACA
Abdiel Capital Advisors
New York
|
+$324M |
| 3 |
Goldman Sachs
New York
|
+$28.7M |
| 4 |
Norges Bank
Oslo,
Norway
|
+$28.4M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$21.2M |
Top Sellers
GDRX Hedge Fund Activity: Q4 2021 in Review
216 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in GoodRx Holdings (GDRX) for Q4 2021, worth a combined $4.99B — down 13% from $5.73B a quarter earlier.
Fund positioning in GDRX was balanced in Q4 2021: 54 funds opened new positions, 54 closed out, 63 added to existing stakes and 61 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $329M. The largest seller was Atreides Management, exiting entirely with an estimated $94.9M sold.
- 216 institutional investors held GoodRx Holdings (GDRX) as of Q4 2021, down from 218 in Q3 2021.
- Funds reported $4.99B of GoodRx Holdings stock for Q4 2021, down 13% quarter-over-quarter.
- 54 funds opened new GoodRx Holdings positions in Q4 2021 and 54 closed out, a net change of 0 holders.
- The largest GoodRx Holdings buyer in Q4 2021 was Morgan Stanley, an estimated $329M added.
- The largest GoodRx Holdings seller in Q4 2021 was Atreides Management, an estimated $94.9M sold.
Based on aggregated 13F filings for Q4 2021.